Age (years) |
|
Median (range) |
75 (63–90) |
Gender |
|
Male |
17 (85%) |
Female |
3 (15%) |
Performance status |
|
0 |
8 (40%) |
1 |
8 (40%) |
2 |
4 (20%) |
Charlson Index |
|
0 |
5 (25%) |
1 |
6 (30%) |
2 |
7 (35%) |
3 |
2 (10%) |
Follow-up time (months) |
|
Median (range) |
27.5 (12-72) |
Chronic obstructive pulmonary disease |
|
Yes |
9 (45%) |
No |
11 (55%) |
T category Numbers correspond to the tumor-node-metastasis system of classification (International Union Against Cancer criteria) |
|
T1 |
4 (20%) |
T2 |
11 (55%) |
T3 |
4 (20%) |
T4 |
1 (5%) |
Stage Numbers correspond to the tumor-node-metastasis system of classification (International Union Against Cancer criteria) |
|
I |
15 (75%) |
II |
4 (20%) |
III |
1 (5%) |
Tumor location |
|
Right upper lobe |
7 (35%) |
Right middle lobe |
2 (10%) |
Right lower lobe |
6 (30%) |
Left upper lobe |
3 (15%) |
Left lower lobe |
2 (10%) |
Histopathology |
|
Squamous cell carcinoma |
8 (40%) |
Adenocarcinoma |
5 (25%) |
Clinical malignancy |
7 (35%) |
Diameter of lung tumor (mm) |
|
Median (range) |
39.5 (24-81) |